M&A Deal Summary

Genzyme Acquires GelTex Pharmaceuticals

On December 25, 2000, Genzyme acquired life science company GelTex Pharmaceuticals

Acquisition Highlights
  • This is Genzyme’s 2nd transaction in the Life Science sector.
  • This is Genzyme’s 4th transaction in the United States.
  • This is Genzyme’s 2nd transaction in Massachusetts.

M&A Deal Summary

Date 2000-12-25
Target GelTex Pharmaceuticals
Sector Life Science
Buyer(s) Genzyme
Deal Type Add-on Acquisition

Target

GelTex Pharmaceuticals

Waltham, Massachusetts, United States
GelTex Pharmaceuticals, Inc. engaged in developing and marketing non-absorbed polymer drugs

Search 177,960 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genzyme

Cambridge, Massachusetts, United States

website


Category Company
Founded 1981
Sector Life Science
DESCRIPTION
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.


DEAL STATS #
Overall 4 of 12
Sector (Life Science) 2 of 9
Type (Add-on Acquisition) 3 of 10
State (Massachusetts) 2 of 2
Country (United States) 4 of 9
Year (2000) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-03-07 Biomatrix

Ridgefield, New Jersey, United States

Biomatrix is a developer and manufacturer of viscoelastic biomaterials for use in orthopedic and other medical applications.

Buy $738M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2001-09-27 Novazyme Pharmaceuticals

Oklahoma City, Oklahoma, United States

Novazyme is a development stage biotechnology company focused on drugs to treat lysosomal storage diseases

Buy $137M